ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

30 4 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

03 4 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

21 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

07 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

06 3 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

26 2 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

22 2 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

20 2 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

05 2 2024 08:01:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 11 2023 15:00:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

09 11 2023 10:02:36 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

06 10 2023 08:03:00 提供 Nasdaq GlobeNewswire

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

03 10 2023 08:03:40 提供 Nasdaq GlobeNewswire

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

19 9 2023 21:49:48 提供 Nasdaq GlobeNewswire

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

10 8 2023 15:00:00 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

20 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

15 5 2023 08:00:00 提供 Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

11 5 2023 18:01:24 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

09 5 2023 08:10:46 提供 Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

28 3 2023 08:39:51 提供 Nasdaq GlobeNewswire